BHC - Bausch Health Companies Inc.

NYSE - NYSE Delayed Price. Currency in USD
23.44
-0.17 (-0.72%)
At close: 4:01PM EDT

23.44 0.00 (0.00%)
After hours: 4:16PM EDT

Stock chart is not supported by your current browser
Previous Close23.61
Open23.61
Bid23.44 x 2200
Ask23.44 x 800
Day's Range23.13 - 23.72
52 Week Range17.20 - 28.45
Volume2,022,683
Avg. Volume3,978,085
Market Cap8.222B
Beta (3Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-4.61
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est30.93
Trade prices are not sourced from all markets
  • Is Bausch Health (BHC) a Great Value Stock Right Now?
    Zacks5 days ago

    Is Bausch Health (BHC) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Aerie Completes Enrollment Under Rhopressa Study in Japan
    Zacks6 days ago

    Aerie Completes Enrollment Under Rhopressa Study in Japan

    Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

  • CNW Group6 days ago

    Bausch + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamins

    BRIDGEWATER, N.J. , July 9, 2019 /CNW/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Ocuvite® Eye Performance vitamins, a nutritional supplement designed to meet the changing needs of consumers while further expanding the company's eye vitamin portfolio. "Today's modern, always-on world has evolved faster than our eyes – from the blue light of computer screens and cell phones to the increased UV exposure from the sun – which can have an impact on our eye health," said Joe Gordon , U.S. president, Bausch + Lomb.

  • PR Newswire7 days ago

    Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6

    LAVAL, Quebec , July 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2019 financial results on Tuesday, Aug. 6, 2019 . Bausch ...

  • Is Bausch Health Becoming a Successful Turnaround Story?
    Market Realist10 days ago

    Is Bausch Health Becoming a Successful Turnaround Story?

    Bausch Health (BHC) has gained 20.13% in the last month and is up by 38.93% in 2019 on a YTD basis.

  • Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
    Zacks10 days ago

    Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

    Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

  • Why Shares of Bausch Health Companies Rocketed Higher in June
    Motley Fool11 days ago

    Why Shares of Bausch Health Companies Rocketed Higher in June

    It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.

  • Benzinga13 days ago

    6 Times These Big Investors Probably Said 'Whoops!'

    Pershing Square Capital’s Bill Ackman has had a roller-coaster of success and failures in recent years. Perhaps no failure has been as highly publicized as his stake in Valeant Pharmaceuticals, which is now Bausch Health Companies Inc (NYSE: BHC). Ackman reportedly first took his massive stake in Valeant back in 2015 at an average price of around $196 per share.

  • Here's Why Dova Pharmaceuticals Stock Jumped Higher Today
    Motley Fool18 days ago

    Here's Why Dova Pharmaceuticals Stock Jumped Higher Today

    The drugmaker's Doptelet therapy just received an expanded approval.

  • Dova Receives Approval for Doptelet in Europe, Stock Up
    Zacks18 days ago

    Dova Receives Approval for Doptelet in Europe, Stock Up

    Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

  • TheStreet.com20 days ago

    Bausch Health Gains on Debt Reduction, Psoriasis-Lotion Launch

    gained on Tuesday after the health-sciences company said it had reduced its debt outstanding and introduced a new psoriasis-treatment lotion. The Laval, Quebec, company said it had paid down an additional $100 million of debt using cash from operations, eliminating any additional "mandatory amortization" for its fiscal 2020 first quarter. Calling the drug one of its "significant seven" -- a collection of products that could garner a predicted $1 billion in sales through 2024 -- Bausch Health expects Duobrii to be a strong revenue driver.

  • Benzinga20 days ago

    Bausch Sees Clearer With Less Debt

    Bausch Health Companies Inc (NYSE: BHC ) jumped 3% on Tuesday after the company announced it has taken a major stride in paying down its massive debt load. Bausch, which changed its name from Valeant Pharmaceuticals ...

  • Zacks20 days ago

    Allergan Up As Analyst Statement Sparks Business Split Rumors

    Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.

  • MarketWatch20 days ago

    Bausch Health to pay down more debt this week, stock rallies

    Bausch Health Companies Inc. said Tuesday it will pay down an additional $100 million worth of debt this week, which will eliminate all mandatory amortization for the first quarter of 2020. The stock rose 1.9% in premarket trading. The maker of pharmaceutical, medical-device and over-the-counter products said it will use cash generated from operations to pay down the senior secured terms loans. The stock has lost 1.6% over the past three months but has rallied 28.6% year to date through Monday, while the S&P 500 has gained 17.5% this year.

  • PR Newswire20 days ago

    Bausch Health To Reduce Debt By Additional $100 Million Using Cash Generated From Operations

    LAVAL, Quebec, June 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it put in notice to pay down an additional $100 million of its senior secured term loans this week, using cash generated from operations. After this payment, the Company will have eliminated all mandatory amortization for the first quarter of 2020. Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

  • PR Newswire20 days ago

    Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

    LAVAL, Quebec, June 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, will be available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug Administration on April 25, 2019, DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation. "The launch of DUOBRII marks the fifth innovative therapy that Ortho Dermatologics has brought forward within the last 30 months," said Bill Humphries, president, Ortho Dermatologics.

  • Barrons.com21 days ago

    Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.

    It has been a roller-coaster day on the market for the two companies behind Vyleesi, an injection that received Food and Drug Administration approval last week to treat low sex drive in women. The drug’s approval received significant news coverage, and much of it focused on the controversy that surrounded the other drug approved for low sex drive in women, Addyi, which has struggled on the market and drawn criticism for its potential side effects. The approval of Addyi, marketed by Sprout Pharmaceuticals, drew significant attention in 2015, and led to the $1 billion acquisition of Sprout by (BHC) now (BHC) (BHC).

  • Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%
    Zacks24 days ago

    Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%

    Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • CNW Group26 days ago

    Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

    BRIDGEWATER, N.J. , June 19, 2019 /CNW/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the company's unique 3-Zone Progressive ™ multifocal design with the stability of its OpticAlign® toric design to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.